

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

MOLECULAR BACKGROUND AND GENOTYPE-PHENOTYPE CORRELATION IN APECED PATIENTS FROM CAMPANIA AND IN THEIR RELATIVES

This is the author's manuscript

Original Citation:

Availability:

This version is available <http://hdl.handle.net/2318/98210> since 2016-07-28T10:44:41Z

Published version:

DOI:10.3275/7677

Terms of use:

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

This is the author's final version of the contribution published as:

D. Capalbo; C. Mazza; R. Giordano; N. Improda; E. Arvat; S. Cervato; L. Morlin; C. Pignata; C. Betterle; M. Salerno.. MOLECULAR BACKGROUND AND GENOTYPE-PHENOTYPE CORRELATION IN APECED PATIENTS FROM CAMPANIA AND IN THEIR RELATIVES. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION. 35 pp: 169-173.
DOI: 10.3275/7677

When citing, please refer to the published version.

Link to this full text:

<http://hdl.handle.net/2318/98210>

1
2
3 1 **MOLECULAR BACKGROUND AND GENOTYPE-PHENOTYPE CORRELATION IN**
4
5 2 **APECED PATIENTS FROM CAMPANIA AND IN THEIR RELATIVES.**
6
7

8
9
10 4 D. Capalbo¹, C. Mazza², R. Giordano³, N. Improda¹, E. Arvat⁴, S. Cervato⁵, L. Morlin⁵, C. Pignata¹,
11
12 5 C. Betterle⁵ and M. Salerno¹
13
14 6

15
16 7 ¹Department of Pediatrics, University “Federico II” of Naples; ²Institute for Molecular Medicine A.
17
18 8 Nocivelli, University of Brescia; ³Department of Clinical and Biological Sciences and ⁴Division of
19
20 9 Endocrinology , Department of Internal Medicine, University of Turin; ⁵Division of Endocrinology,
21
22
23 10 Department of Medical and Surgical Sciences, University of Padua, Italy
24
25 11

26
27 12 Short title: Genotype in APECED patients from Campania
28

29 13 Key Words: APECED, AIRE, genotype-phenotype correlation, autoimmune diseases, pediatric
30
31 14 endocrinology
32
33

34 15 Correspondence and reprints requests to

35
36 16 Mariacarolina Salerno, MD, PhD, Department of Pediatrics, “Federico II” University of Naples,
37
38 17 Italy, Tel +390817464339, FAX +390815451278, Email: salerno@unina.it
39

40 18 Acknowledgements: this study was supported in part by the EU Research Project EurAPS:

41
42 19 Autoimmune polyendocrine syndrome type I—a rare disorder of childhood as a model for
43
44 20 autoimmunity, contract number LSHM-CT 2005-005223, and in part by a grant from European Union
45
46 21 Seventh Framework Programme, the Euradrenal project: Pathophysiology and Natural Course of
47
48 22 Autoimmune Adrenal Failure in Europe. Grant Agreement No. 2008-201167.
49
50
51 23

52
53 24 Word counts: 2479
54

55 25 Number of references: 26
56

57 26 Number of tables: 1
58

59 27 Number of figures: 1
60

28 Disclosure summary: the authors have nothing to declare.

1
2
3 1
4
5 2 **LIST OF ABBREVIATIONS**
6
7

8 3 Addison's disease: AD

9
10 4 Autoimmune Hepatitis: AH

11
12 5 Atrophic Gastritis: AG

13
14 6 Autoimmune Thyroiditis: AT

15
16 7 AutoImmune REgulator gene: AIRE

17
18 8 Autoimmune Polyendocrinopathy - Candidiasis – Ectodermal - Distrophy: APECED

19
20 9 Autoantibodies: Abs

21
22 10 Autoantibodies against Adrenal Cortex: ACA

23
24 11 Autoantibodies against Aromatic-L-Aminoacid decarboxylase: AADCABs

25
26 12 Autoantibodies against Glutamic acid decarboxylase: GADA

27
28 13 Autoantibodies against Islet cells: ICA

29
30 14 Autoantibodies against Intrinsic Factor: IFA

31
32 15 Autoantibodies against 17 α -hydroxylase: 17 α -OHABs

33
34 16 Autoantibodies against 21 hydroxylase: 21-OHABs

35
36 17 Autoantibodies against melanin producing cells: MPCA

37
38 18 Autoantibodies against Parietal cells: PCA

39
40 19 Autoantibodies against Side-chain cleavage enzyme: sccAbs

41
42 20 Autoantibodies against Steroid-producing cells: StCA

43
44 21 Autoantibodies against tissue transglutaminase: tTgAbs

45
46 22 Autoantibodies against Thyroglobulin: TgAbs

47
48 23 Autoantibodies against Thyroid microsomal: TMABs

49
50 24 Autoantibodies against Tryptophan hydroxylase: TPHABs

51
52 25 Autoantibodies against Thyroperoxidase: TPOABs

53
54 26 Caspase-recruitment domain: CARD

55
56 27 Chronic Hypoparathyroidism: CH

57
58 28 Chronic Mucocutaneous Candidiasis: CMC

- 1
- 2
- 3 1 Ectodermal Dystrophy: ED
- 4
- 5 2 Growth Hormone Deficiency: GHD
- 6
- 7
- 8 3 Hypergonadotropic Hypogonadism: HH
- 9
- 10 4 Posterior Reversible Encephalopathy Syndrome: PRES
- 11
- 12 5
- 13
- 14 6
- 15
- 16 7
- 17
- 18 8
- 19
- 20 9
- 21
- 22 10
- 23
- 24 11
- 25
- 26 12
- 27
- 28 13
- 29
- 30 14
- 31
- 32 15
- 33
- 34 16
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

1
2
3 **1 ABSTRACT**
4

5 **Background:** Autoimmune-Polyendocrinopathy-Candidiasis-Ectodermal-Dystrophy (APECED)
6
7 is a recessive disease, caused by mutations in the AutoImmune REgulator (AIRE) gene. Different
8
9 mutations are peculiar of particular populations. In Italy three hot spots areas where APECED
10
11 shows an increased prevalence, have been identified in Sardinia, Apulia and in the Venetian
12
13 region.
14

15
16 **Aim:** in this study we analyzed AIRE mutations and genotype-phenotype correlation in
17
18 APECED patients originating from Campania and in their relatives.
19

20
21 **Patients and methods:** in six patients affected with APECED clinical findings, genetic analysis
22
23 of AIRE and APECED-related autoantibodies were performed.
24

25 **Results:** all patients carried at least one mutation on exon 1 or on splice-site flanking exon 1.
26
27 Two siblings carried a complex homozygous mutation [IVS1 + 1G>C; IVS1 + 5delG] on intron
28
29 1; two patients were compound heterozygous for [T16M]+[W78R] (exons 1+2); one patient was
30
31 compound heterozygous for [A21V]+[C322fs] (exons 1+8) and another was homozygous for
32
33 [T16M]+[T16M] on exon 1. Expression of the disease showed wide variability while circulating
34
35 autoantibodies paralleled to phenotype in each patient. Analysis of relatives allowed the
36
37 identification of 8 heterozygotes. None of heterozygous subjects presented major findings of
38
39 APECED.
40

41
42 **Conclusions:** mutations localized on exon 1 and the region flanking exon 1 are common in
43
44 APECED patients originating from Campania. Genotype-phenotype correlation failed to reveal a
45
46 relationship between detected mutations and clinical expression. Mutations in heterozygosis in
47
48 AIRE gene are not associated to major findings of APECED.
49

50
51 2
52
53 3
54
55 4
56
57 5
58
59 6
60
7

1 INTRODUCTION

2 Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal-Dystrophy (APECED) is a rare autosomal
3 recessive disease (OMIM 240300) which affects many tissues especially endocrine glands (1). The
4 diagnosis is primarily based on the presence of two out of the three most common clinical features:
5 chronic mucocutaneous candidiasis (CMC), chronic hypoparathyroidism (CH) and Addison's
6 disease (AD). CMC is often the first clinical manifestation to appear before the age of 5 year,
7 followed by CH and later by AD. APECED is caused by mutations in the AutoImmune REgulator
8 gene (AIRE), which maps to chromosome 21q22.3 (2, 3) and encodes a 55-kDa protein that acts as a
9 transcription regulator. Over 60 mutations have by now been localized in the AIRE genes of
10 different APECED patients (4). Even though it occurs through the world, its incidence is higher in
11 some genetically isolated populations. The estimated prevalence of APECED is 1:9.000 in Iranian
12 Jewes (5), 1:25.000 in Finns (6,7) and 1:14.400 in Sardinians (8). Some different mutations have
13 been found to be peculiar of specific areas. R257X is the most common mutation among Finnish and
14 other European patients (9-11), 1094-1106del113 (or 967-979del13 bp) is the most common
15 mutation in British (12), Irish (13), North America (14,15) and Norwegian patients (16) and the
16 Y85C mutation is more frequent among Iranian Jewes (17).

17 In Italy three hot spots areas where APECED shows an increased prevalence, have been identified
18 in Sardinia, Apulia and in the Venetian region. Moreover, both in Sardinia and Apulia a peculiar
19 mutation of AIRE has been identified: the mutation R139X on exon 3 in Sardinia (18) and the
20 mutation W78R on exon 2 in Apulia (19). In Veneto region AIRE gene mutations were different
21 from the other Italian regions but similar to that identified in finnish and anglo-saxon patients (20).
22 A typical mutation has been recently identified also in Sicily (R203X on exon 5) (20).

23 However, the different mutations have not to date been convincingly associated with particular
24 disease manifestations (4).

25 To the best of our knowledge, only one patient with AIRE mutation was described from Campania
26 so far, having the homozygous mutation c1314-1326 del13/insGT on exon 11 (21).

1
2
3 1 Aim of this study was to characterized genotype and phenotype of 6 new APECED patients
4
5 2 originating from Campania, in the attempt to evaluate their genotype-phenotype correlation.
6
7
8 3 Moreover we studied the relatives of these patients in order to evaluate the clinical and biochemical
9
10 4 effects of heterozygous mutations of the gene.
11
12 5

13 6 **PATIENTS AND METHODS**

14 7 **Patients**

15
16 8 Six patients originating from Campania (a region of Southern Italy) affected with APECED (5 F, 1
17
18 9 M), were investigated. In all of them the onset of the disease was in early childhood; two of them were
19
20
21 10 followed up until young adult age. Patients were selected for the presence of signs or symptoms
22
23 11 suggestive of APECED. Two of the three major criteria of APECED (hypoparathyroidism and chronic
24
25 12 candidiasis) were present at diagnosis in 5 of them. One patient presented only candidiasis as major
26
27 13 criteria, but she was enrolled for the association of chronic mucocutaneous candidiasis with other
28
29 14 autoimmune diseases (vasculitis, autoimmune thyroiditis, alopecia) in early childhood. The patients
30
31 15 were originating from 5 unrelated families. They were all originating from Campania region, but the
32
33 16 areas where they lived or from they had their origins were not close to each other. Consanguinity
34
35 17 between the parents was identified in only one family with two affected children (third cousins). In the
36
37 18 6 patients a complete clinical and biochemical evaluation of the major and minor signs and symptoms
38
39 19 of APECED disease, molecular analysis of AIRE gene and assessment of all APECED-related
40
41 20 autoantibodies were performed.
42
43
44
45
46

47 21 Major and minor clinical features of APECED, molecular analysis of AIRE and autoantibodies
48
49 22 related to APECED syndrome were also evaluated in eight out of the ten parents of the affected
50
51 23 patients (4M, 4F) (aged 40±10 years), who gave their consent. They all were originating from
52
53 24 Campania.
54
55
56
57

58 26 **Analysis of AIRE gene**

59 27 Genomic DNA was extracted from peripheral blood by Maxwell 16 Systems (Promega Corporation,
60 28 Madison WI, USA). All 14 exons of the AIRE gene were amplified with the use of primers located

1 on the respective flanking introns (17) and were analyzed by direct sequencing using the Big Dye
2 terminator cycle sequencing Kit and ABI PRISM 3130 automated sequencer (Applied Biosystems,
3 Foster City, CA, USA). The analysis included sequencing of the donor/acceptor sites of all the
4 introns.

6 **Autoantibodies**

7 Autoantibodies against the following antigens were performed by classical indirect
8 immunofluorescence technique, complement fixation, ELISA or RIA, as appropriate: Thyroglobulin
9 (TgAbs), Thyroid microsomal (TMAbs), Thyroperoxidase (TPOAbs), Parietal cells (PCA), Intrinsic
10 factor (IFA), Islet cells (ICA), Glutamic acid decarboxylase (GADA), tissue transglutaminase
11 (tTgAbs), Adrenal cortex (ACA), Steroid-producing cells (StCA), melanin producing cells (MPCA).
12 Autoantibodies to 21-hydroxylase (21-OHAbs) were tested using RSR's kit (22). 17 α -hydroxylase
13 (17 α -OHAbs) as well as side-chain cleavage enzyme (sccAbs) autoantibodies were measured using
14 specific and sensitive immunoprecipitation assays (IPAs) (23). Autoantibodies to Aromatic-L-
15 Aminoacid decarboxylase (AADCAbs) and Tryptophan hydroxylase (TPHAbs) were measured in an
16 immunoprecipitation assay using (35)S-labelled full length and fragments of TPH and AADC (24).

18 **RESULTS**

19 **Clinical presentation and autoantibodies**

20 Clinical characteristics and autoantibodies' profile of each patient are reported in Table 1.

21 **Patient 1** was born from consanguineous parents (third cousins). He first presented at 1.5
22 years of age with a history of transient hypertransaminasemia. At the age of 5 years, he suddenly
23 developed an unusually severe phenotype with many signs and symptoms outbreaking over a six
24 month period. In fact, the physical examination revealed the presence of vitiligo, nail dystrophy,
25 alopecia, oral candidiasis and hepatosplenomegaly. He also suffered from alternating stipsis/diarrhea
26 and chronic abdominal pain. Laboratory testing led to diagnosis of autoimmune hepatitis, chronic
27 hypoparathyroidism, chronic thyroiditis and Addison's disease. Endoscopy revealed the presence of
28 atrophic gastritis of the body. Six months after the onset of this accelerated phase, the patient

1 suddenly developed a severe neurological syndrome with neuroradiological findings suggestive of
2 Posterior Reversible Encephalopathy Syndrome (PRES), a life-threatening event never described
3 before in APECED patients (**Table 1**) (25). Screening of autoantibodies revealed the presence of
4 TgAbs, TMAbs, TPOAbs, PCA, ACA, 21-OH-Abs, StCA, 17 α -OHAbs, AADCABs, TPHAbs and
5 MPCA. sccAbs and GADA were negative (**Table 1**).

6 **Patient 2** (the younger sister of patient 1), presented at 4 years of age with chronic
7 hypoparathyroidism, chronic mucocutaneous candidiasis and ectodermal dystrophy (**Table 1**).
8 During three years of follow-up, she did not develop any other feature of the disease. None of the
9 autoantibodies tested resulted positive (**Table 1**).

10 **Patient 3** first presented at the age of 2 years with chronic mucocutaneous candidiasis,
11 chronic abdominal pain and alternating stipsis/diarrhea. At the age of 8 years she was diagnosed as
12 having chronic hypoparathyroidism, Addison's disease, growth hormone deficiency, enamel
13 dysplasia and alopecia. At the age of 14 years she developed ungueal dystrophy, chronic thyroiditis
14 and hypergonadotropic hypogonadism (**Table 1**). Autoantibodies' profile revealed the presence of
15 TgAbs, TMAbs, TPOAbs, ICA, ACA, 21-OH-Abs, StCA, 17 α -OHAbs, sccAbs, AADCABs and
16 TPHAbs (**Table 1**).

17 **Patient 4** first presented at the age of 8 months with vasculitis and splenomegaly. Thereafter,
18 at the age of 2 years, she developed chronic mucocutaneous candidiasis and, at the age of 5 years,
19 severe alopecia, chronic thyroiditis and recurrent abdominal pain with alternating stipsis/diarrhea
20 (**Table 1**). Autoantibodies' profile revealed the presence of TgAbs, TMAbs, PCA, ACA, 21-OH-Abs
21 StCA, 17 α -OHAbs and sccAbs (**Table 1**).

22 **Patient 5** presented with chronic hypoparathyroidism at the age of 2 years. At the age of 3
23 years she developed Addison's disease, chronic oral candidiasis and ungueal dystrophy (**Table 1**).
24 Only 21-OHAbs resulted to be positive. sccAbs, AADCABs and TPHAbs were negative. During 4
25 years of follow-up, she did not show any other signs, symptoms or autoantibody (**Table 1**).

26 **Patient 6** first developed chronic hypoparathyroidism, enamel dysplasia and chronic
27 mucocutaneous candidiasis at the age of 6 years. At the age of 15 years, Addison's disease and

1 alopecia were also diagnosed (**Table 1**). Autoantibodies' profile revealed positivity for ACA, 21-
2 OHAbs, and sccAbs (**Table 1**).

3 Noteworthy, autoantibodies paralleled clinical phenotype in each case. Infact, no antibodies were
4 detected in patient 2 with only a mild expression of the disease whereas several autoantibodies were
5 detected in patients 1 and 3 with a more severe expression of APECED. Globally, the most prevalent
6 autoantibodies found were those against 21-Hydroxylase.

7 8 **AIRE mutation analysis**

9 Five different AIRE mutations were detected. Interestingly, all patients carried at least one mutation
10 on exon 1 or on splice donor site of intron 1 (**Table 1**).

11 Two siblings carried a complex homozygous mutation in intron 1, consisting of a substitution of
12 IVS1 + 1G by C accompanied in *cis* by a single nucleotide deletion at IVS1 + 5G residue [IVS1 +
13 1G>C; IVS1 + 5delG]. Two patients were compound heterozygous for [T16M]+[W78R] on exons 1
14 and 2 respectively; one patient was compound heterozygous for [A21V]+[C322fs] on exons 1 and 8,
15 respectively and one patient was homozygous for [T16M] +[T16M] on exon 1. None of the
16 mutation described is a novel mutation but the complex variant [IVS1 + 1G>C; IVS1 + 5delG] is
17 uncommon. Figure 1 summarizes on both the gene and protein domains mutations detected in this
18 study, as well as those previously described.

19 20 **Relatives**

21 Analysis of AIRE gene revealed that all parents were heterozygotes for one of the mutations found in
22 the patients, confirming autosomal recessive model of inheritance of APECED. Three of them had a
23 mutation on exon 1, two had a complex mutation in intron 1, two had a mutation on exon 2 and one
24 had a mutated allele on exon 8.

25 Clinical evaluation revealed that none of them was affected by one of the major features of
26 APECED. Four of them (3F, 1M) had positive autoantibodies: two against PC, one against TM and
27 another against both Tg and PC.

1
2
3 1 **DISCUSSION**
4

5 2 Recent studies have documented that in four Italian regions different AIRE gene mutations have
6
7 been identified. Typical mutations have been identified in Sardinia (R139X on exon 3) (18) , in
8
9 Apulia (W78R on exon 2) (19), in Veneto (R257X on exon 6 and 8) and in Sicily (R203X on exon 5)
10
11 (20).
12

13
14 6 In Campania, a region of the Southern Italy, only one case with AIRE mutation has been described
15
16 so far, carrying an homozygous mutation on exon 11 (c1314-1326 del 13/insGT) (21).
17

18
19 8 In our study we have delineated the molecular pathology and the clinical spectrum of 6 more
20
21 probands affected with APECED originating from this region.
22

23
24 10 Our results suggest that mutations localized on exon 1 or on the region flanking exon 1, being
25
26 present either in compound heterozygosis or homozygosis, are relatively common in APECED
27
28 patients originating from Campania.

29
30 13 Exon 1 and the region flanking exon 1, are localized at the aminoterminal of AIRE. This domain
31
32 was long referred to as a homogeneously staining region (HSR) domain but recent evidence suggest
33
34 that this region encompasses a caspase-recruitment domain (CARD) (26). As shown in figure 1, in
35
36 this area most other missense mutations have been located. CARD domains are involved in the
37
38 process of homo- or hetero-dimerization. Aire's CARD is needed for a correct dimerization of AIRE
39
40 and interactions with other transcriptional control proteins. Thus, missense mutations and also small
41
42 deletions affecting this domain lead to the production of a functionally defective protein due to the
43
44 loss of its homodimerization properties (26).
45
46

47
48 21 None of the mutations detected in our patients is novel. However the complex homozygous mutation
49
50 reported in the two siblings is uncommon. The sequence variant [IVS1 + 1G>C; IVS1 + 5delG]
51
52 consists of two mutations, each likely to affect the splicing of intron 1. The IVS1 + 1G is 100%
53
54 conserved in the major-class introns so that its change into C must render the splice site
55
56 nonfunctional. The IVS1 + 5delG is also likely to have a negative effect because in the major-class
57
58 introns at the IVS+5 position only G,A or T occur. This mutation has never been reported in
59
60 APECED patients from Italy. So far, the IVS1 + 1G>C; IVS1 + 5delG mutation has been described
28 in heterozygous state with the R257X in a single individual from Poland (10).

1 Noteworthy, in the six patients described the phenotype was characterized by the presence of several
2 unusual (GH deficiency, vasculitis) and life-threatening (PRES, Chronic Hepatitis) complications of
3 the disease. In particular, the PRES is a neurological acute syndrome never described before in
4 APECED patients (25). GH deficiency and vasculitis also represent very rarely a feature of the
5 disease. Moreover, three of our six patients, presented Addison's disease in early childhood, whereas
6 it is commonly reported after the second decade of life. In patients with early development of
7 Addison, life-threatening complications (such as autoimmune hepatitis and squamous cell carcinoma
8 of the oral mucosa) can occur, and therefore they should be followed more closely.

9 Analysis of genotype-phenotype correlation in our subjects failed to reveal a clear relationship, as
10 previously reported in other series of patients. All patients had an early onset of the disease, but the
11 phenotype and the severity of the disease widely differed even between patients with the same
12 mutation of AIRE. In particular the 2 siblings carrying the same complex homozygous mutation
13 (patient 1 and 2) showed a wide heterogeneity of clinical expression: one patient developed a severe
14 phenotype culminating in a life-threatening event, whereas his sister presented with only a mild
15 phenotype. Moreover, their phenotypes were different from the only other patient from Poland
16 carrying the same complex mutation. Patient 3 and 4, presenting the same missense mutations
17 [T16M]+[W78R], also widely differed in their phenotype: the first patient, in fact, had only a mild
18 phenotype characterized by alopecia, ectodermal dystrophy and candidiasis, whereas the second
19 patient developed a severe phenotype, with many signs and symptoms, since the first decade of life.
20 Also in patients with Addison, the early development of disease was not apparently related to the
21 genotype in that the three patients affected carried different mutations of the gene.

22 Autoantibodies paralleled clinical phenotype in each case, confirming their role in the pathogenesis
23 of the disease.

24 The study of the relatives confirmed that the heterozygous state for AIRE mutations is not associated
25 to the presence of major signs or symptoms correlated to APECED syndrome, as previously reported
26 (20). Accordingly with Cervato et al, in fact, in our heterozygous subjects we only detected latent
27 autoimmune diseases as demonstrated by the presence of thyroid or PC autoantibodies in 4 of the 8
28 studied heterozygous. We found only a slight prevalence in female versus male, whereas no

1 differences were detected on the basis of age. However, in all relatives, also those initially negative,
2 a longitudinal evaluation of antibodies could be useful in order to identify those subjects that might
3 develop clinical or subclinical disease over time.

4 In conclusion we described 6 patients characterized by several unusual and life-threatening
5 complications of APECED. Our analysis failed to reveal a clear genotype-phenotype correlation
6 according to previous reports. However, our data demonstrate that APECED in Campania region is
7 more frequent than reported so far and that mutations on exon 1 and on region flanking exon 1 of
8 AIRE gene are common in patients originating from this region.

References

1. Betterle C, Greggio NA & Volpato M. Clinical Review 93: Autoimmune polyglandular syndrome type 1. *J Clin Endocrinol Metab* 1998, 83: 1049-1055.
2. Finish-German APECED Consortium. An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zinc-finger domains. *Nat Genet*, 17: 399-403.
3. Nagamine K, Peterson P, Scott HS, et al. Positional cloning of the APECED gene. *Nat Genet* 1997, 17: 393-398.
4. Mathis D & Benoist C Aire. *Annu Rev Immunol* 2009, 27: 287-312.
5. Zlotogora J & Shapiro MS. Polyglandular autoimmune syndrome type I among Iranian Jews. *J Med Genet* 1992, 29: 824-826.
6. Aaltonen J, Bjorses P, Sandkuijl L, Perheentupa J, Peltonen L. An autosomal locus causing autoimmune disease: autoimmune polyglandular disease type I assigned to chromosome 21. *Nat Genet* 1994, 8: 83-87.
7. Ahonen P, Myllarniemi S, Sipila I, Perheentupa J. Clinical variation of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in a series of 68 patients. *N Engl J Med* 1990, 322: 1829-1836.

- 1
2
3 1 **8.** Rosatelli MC, Meloni A, Devoto M et al. A common mutation in Sardinian autoimmune-
4
5 2 polyendocrinopathy-candidiasis-ectodermal dystrophy patients. *Hum Genet* 1998, 103: 428-
6
7 3 434.
- 8
9 4 **9.** Podkrajsek KT, Bratanic N, Krzysnik C, Battelino T. Autoimmune regulator-1 messenger
10
11 5 ribonucleic acid analysis in a novel intronic mutation in a cohort of autoimmune
12
13 6 polyendocrinopathy-candidiasis-ectodermal dystrophy patients. *J Clin Endocrinol Metab* 2005,
14
15 7 90: 4930-4935.
- 16
17 8 **10.** Stolarski B, Pronicka E, Korniszewski L et al. Molecular background of polyendocrinopathy-
18
19 9 candidiasis-ectodermal dystrophy syndrome in a Polish population: novel AIRE mutations and
20
21 10 an estimate of disease prevalence. *Clin Genet* 2006, 70: 348-354.
- 22
23 11 **11.** Scott HS, Heino M, Peterson P et al. Common mutations in autoimmune polyendocrinopathy-
24
25 12 candidiasis-ectodermal-dystrophy patients of different origins. *Mol Endocrinol* 1998, 12: 1112-
26
27 13 1119.
- 28
29 14 **12.** Pearce SH, Cheetham T, Imrie H et al. A common and recurrent 13-bp deletion in the
30
31 15 autoimmune regulator gene in British kindreds with autoimmune polyendocrinopathy Type 1.
32
33 16 *Am J Hum Genet* 1998, 63: 1675-1684.
- 34
35 17 **13.** Dominguez M, Crushell E, Ilmarinen T et al. Autoimmune polyendocrinopathy-candidiasis-
36
37 18 ectodermal dystrophy (APECED) in the Irish population. *J Pediatr Endocrinol Metab* 2006, 19:
38
39 19 1343-1352.
- 40
41 20 **14.** Wang CY, Davoodi-Semiromi A, Huang W, Connor E, Shi JD, She JX. Characterization of
42
43 21 mutations in patients with autoimmune Polyglandular syndrome type 1 (APS 1). *Hum Genet*
44
45 22 1998, 103: 681-685.
- 46
47 23 **15.** Heino M, Scott HS, Chen Q et al. Mutation analyses of North American APS-1 patients. *Hum*
48
49 24 *Mutat* 1999, 13: 69-74.
- 50
51 25 **16.** Wolff ASB, Erichsen MM, Meager A et al. Autoimmune polyendocrine syndrome type 1 (APS
52
53 26 D) in Norway-phenotypic variation, autoantibodies and novel mutations in the autoimmune
54
55 27 regulator (AIRE) gene. *J Clin Endocrinol Metab* 2007, 92: 595-603.

- 1
2
3 1 **17.** Bjorses P, Halonen M, Palvimo JJ et al. Mutations in the AIRE gene: effects on subcellular
4 location and transactivation function of the autoimmune polyendocrinopathy-candidiasis-
5 ectodermal dystrophy protein. *Am J Hum Genet* 2000, 66: 378-392.
6
7
8
9
10 4 **18.** Clemente MG, Meloni A, Obermyer-Straub P, Frau F, Manns MP, De Virgiliis S. Two
11 cytochrome P450 are major hepatocellular autoantigens in autoimmune polyglandular
12 syndrome type 1. *Gastroenterology* 1998, 114: 324-328.
13
14
15
16 7 **19.** Meloni A, Perniola R, Faà V, Corvaglia E, Cao A, Rosatelli MC. Delineation of the molecular
17 defects in the AIRE gene in autoimmune polyendocrinopathy-candidiasis-ectodermal
18 dystrophy patients from Southern Italy. *J Clin Endocrinol Metab* 2002, 87: 841-846.
19
20
21
22
23 10 **20.** Cervato S, Mariniello B, Lazzarotto F et al. Evaluation of the autoimmune regulator (AIRE)
24 gene mutations in a cohort of Italian patients with autoimmune-polyendocrinopathy-
25 candidiasis-ectodermal-dystrophy (APECED) and in their relatives. *Clin Endocrinol* 2009, 70:
26 421-428.
27
28
29
30
31
32 14 **21.** Lintas C, Cappa M, Comparcola D, Nobili V, Fierabbracci A. An 8-year-boy with autoimmune
33 hepatitis and *Candida* onychosis as the first symptoms of autoimmune polyglandular syndrome
34 (APS 1): identification of a new homozygous mutation in the autoimmune regulator gene
35 (AIRE). *Eur J Pediatr* 2008, 167: 949-953.
36
37
38
39
40
41 18 **22.** Tanaka H, Perez MS, Powell M et al. Steroid 21-Hydroxylase Autoantibodies: Measurements
42 with a New Immunoprecipitation Assay. *J Clin Endocrinol Metab* 1997, 82: 1440-1446.
43
44
45 20 **23.** Chen S, Sawicka J, Betterle C et al. Autoantibodies to steroidogenic enzymes in autoimmune
46 polyglandular syndrome, Addison's disease, and premature ovarian failure. *J Clin Endocrinol*
47 *Metab* 1996, 81: 1871-1876.
48
49
50
51
52 23 **24.** Dal Pra C, Chen S, Betterle C et al. Autoantibodies to human tryptophan hydroxylase and
53 aromatic L-aminoacid decarboxylase. *Eur J Endocrinol* 2004, 150: 313-321.
54
55
56 25 **25.** Capalbo D, Elefante A, Spagnuolo MI et al. Posterior reversible encephalopathy syndrome
57 during an accelerated phase of a severe APECED phenotype due to an uncommon mutation of
58 AIRE. *Clin Endocrinol* 2008, 69: 511-513.
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 **26.** Ferguson BJ, Alexander C, Rossi SW et al. AIRE's CARD revealed, a new structure for
2 central tolerance provokes transcriptional plasticity. J Biol Chem 2008, 283:1723-1731.

1
2 **Table 1: Clinical manifestations, autoantibodies and AIRE mutations in the 6 APECED patients from Campania**
3
4

	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5	Patient 6
Sex	M	F	F	F	F	F
Age at the onset (years)	1.5	4.0	2.0	0.7	2.0	6.0
Symptoms/Signs	CMC CH AD AT AG ED AH Stipsis/diarrhea Alopecia Vitiligo PRES	CMC CH ED	CMC CH AD HH AT ED Enamel dysplasia Stipsis/diarrhea Alopecia GHD	CMC AT Stipsis/diarrhea Alopecia Vasculitis	CMC CH AD ED	CMC CH AD Enamel dysplasia Alopecia

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Positive Autoantibodies	TgAbs TMAbs TPOAbs PCA ACA 21OHAbs StCA 17- α -OHAbs AADCAbs TPHabs MPCA		TgAbs TMAbs TPOAbs ICA ACA 21-OHAbs StCA 17- α -OHAbs sccAbs AADCAbs TPHabs	TgAbs TMAbs PCA ACA 21-OHAbs StCA 17- α -OHAbs sccAbs	21-OHAbs	ACA 21-OHAbs sccAbs
Mutation	IVS1+1G>C;IVS1+5delG	IVS1+1G>C;IVS1+5delG	T16M/W78R	T16M/W78R	A21V/C322fs	T16M/T16M
Exons	1/1	1/1	1/2	1/2	1/8	1/1

AD, Addison’s disease; AG, Atrophic Gastritis; AH, Autoimmune Hepatitis; AT, Autoimmune Thyroiditis; CH, Chronic Hypoparathyroidism; CMC, Chronic Mucocutaneous Candidiasis; ED, Ectodermal Dystrophy; HH, Hypergonadotrophic Hypogonadism; GHD, Growth Hormone Deficiency; PRES, Posterior Reversible Encephalopathy Syndrome.

AADCAbs, autoantibodies against Aromatic L-Amino Acid Decarboxylase; ACA, autoantibodies against Adrenal Cortex; GADA, autoantibodies against Glutamic Acid Decarboxylase; 17 α -OHAbs, autoantibodies against 17 α -Hydroxylase; 21-OHAbs, autoantibodies against 21-Hydroxylase; ICA, autoantibodies against Islet Cells; MPCA, autoantibodies against Melanin Producing Cells; PCA, autoantibodies against Parietal Cells; sccAbs, autoantibodies against side chain cleavage enzyme; StCA, autoantibodies against Steroid Producing Cells; TgAbs, autoantibodies against Thyroglobulin; TMAbs, autoantibodies against Thyroid Mycosomal; TPOAbs, autoantibodies against Thyroperoxidase; TPHAbs, autoantibodies against Tryptophan Hydroxylase.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1. AIRE gene (top) and corresponding protein (bottom) with functional domains. Mutations detected so far are listed. Mutations found in our patients are in bold.

254x190mm (96 x 96 DPI)